Methylphenidate Extended-release

— THERAPEUTIC CATEGORIES —
  • ADHD
  • Sleep-wake disorders

Methylphenidate Extended-release Generic Name & Formulations

General Description

Methylphenidate HCl 10mg, 20mg; ext-rel tabs.

Pharmacological Class

CNS stimulant.

How Supplied

Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL

Methylphenidate Extended-release Indications

Indications

Attention deficit hyperactivity disorder.

Methylphenidate Extended-release Dosage and Administration

Adults and Children

Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.

Methylphenidate Extended-release Contraindications

Contraindications

During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.

Methylphenidate Extended-release Boxed Warnings

Boxed Warning

Drug abuse and dependence.

Methylphenidate Extended-release Warnings/Precautions

Warnings/Precautions

History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.

Methylphenidate Extended-release Pharmacokinetics

See Literature

Methylphenidate Extended-release Interactions

Interactions

See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.

Methylphenidate Extended-release Adverse Reactions

Adverse Reactions

Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.

Methylphenidate Extended-release Clinical Trials

See Literature

Methylphenidate Extended-release Note

Not Applicable

Methylphenidate Extended-release Patient Counseling

See Literature

Methylphenidate Extended-release Generic Name & Formulations

General Description

Methylphenidate HCl 10mg, 20mg; ext-rel tabs.

Pharmacological Class

CNS stimulant.

How Supplied

Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL

Methylphenidate Extended-release Indications

Indications

Narcolepsy.

Methylphenidate Extended-release Dosage and Administration

Adults and Children

Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.

Methylphenidate Extended-release Contraindications

Contraindications

During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.

Methylphenidate Extended-release Boxed Warnings

Boxed Warning

Drug abuse and dependence.

Methylphenidate Extended-release Warnings/Precautions

Warnings/Precautions

History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.

Methylphenidate Extended-release Pharmacokinetics

See Literature

Methylphenidate Extended-release Interactions

Interactions

See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.

Methylphenidate Extended-release Adverse Reactions

Adverse Reactions

Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.

Methylphenidate Extended-release Clinical Trials

See Literature

Methylphenidate Extended-release Note

Not Applicable

Methylphenidate Extended-release Patient Counseling

See Literature